Study identifier:9238SZ/0001
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
An open, multicenter phase II trial evaluating the antitumour efficacy of Faslodex® (fulvestrant) in postmenopausal women with advanced breast cancer failing non-steroidal or steroidal aromatase inhibitors
Breast Neoplasms
Phase 2
No
Fulvestrant
Female
93
Interventional
N/A
Allocation: Non-randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Feb 2007 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
The primary objective of the study is to assess the activity of fulvestrant in postmenopausal women with advanced breast cancer failing treatment with non-steroidal or steroidal aromatase inhibitors by estimating the Clinical Benefit Rate
Location
Location
Lausanne, Switzerland
Location
St.Gallen, Switzerland
Location
Bern, Switzerland
Location
Aarau, Switzerland
Location
Genf, Switzerland
Location
Mendrisio, Switzerland
Location
Milano, Switzerland
Location
Leuven, Belgium
Arms | Assigned Interventions |
---|
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.